argenx VYVGART revenue climbs 60% to $1.5 billion

• argenx reported second-quarter VYVGART product sales of $1.52 billion, up 60% year over year and 17% sequentially.
• argenx shares rose about 4.4% to €791.60 in Brussels trading following the results.
• The company expanded VYVGART’s US label and expects key myositis and MMN trial results during the second half of 2026.

argenx (NASDAQ:ARGX) reported second-quarter VYVGART product sales of $1.52 billion, up 60%, as operating profit reached $494 million.

Product sales increased from $949 million one year earlier and $1.30 billion in Q1, while diluted EPS rose from $3.74 to $7.32.

During the period under review, argenx expanded the US VYVGART and VYVGART Hytrulo labels to all adult generalized myasthenia gravis serotypes.

Following the announcement, argenx's share price was up 4.4% at €791.60 in Brussels trading.

argenx ended June with $5.2 billion in cash and current financial assets, up from $4.4 billion at December 2025.

The company expects myositis results in Q3 and MMN results in Q4 as it advances its broader Vision 2030 pipeline.